Dr. Mitchell Finer serves as CEO of Life Edit Therapeutics, an ElevateBio company, and President of Research and Development at ElevateBio. He is a co-founder of ElevateBio and serves on its Board of Directors. Dr. Finer also serves as an executive partner at MPM Capital.

Formerly he served as Chief Scientific Officer of Bluebird Bio, where he led the team that conceived of and developed three approved products: Abecma for the treatment of multiple myeloma, Zynteglo for the treatment of beta thalassemia and Skysona for the treatment of childhood cerebral adrenoleukodystrophy. He has served as founder, executive officer or board member at multiple cell therapy, gene therapy and regenerative medicine companies over the last 33 years, including Adverum Biotechnologies, Bluebird Bio, Coda Biotherapeutics, Cell Genesys, the Gencell division of Aventis Pharma (now Sanofi), Genteric, Inc., Intracel Corporation, Novacell (now Viacyte, acquired by Vertex), Oncorus, Inc., Semma Therapeutics, Turmeric Acquisition Holdings, and TCR2 Therapeutics.

His efforts have spanned discovery through market launch of cell gene therapy and regenerative medicine products in the US, Europe and Asia. He has also worked on many of the innovations for manufacture of these products. Currently, he focuses his efforts on changing the way medicine is practiced through the development of ex vivo and in vivo gene edited products leveraging Life Edit's RNA guided nuclease and base editing platform.